AKT1 and breast carcinoma: For example, significant synergisms in terms of reducing cell proliferation and induction of apoptosis were observed with the combination of ipatasertib, an AKT inhibitor, or taselisib, a PI3K inhibitor, and anti-microtubule agents including paclitaxel, vinorelbine, and eribulin in PIK3CA mutant breast cancer cell lines in vitro [40].